Rezdiffra works directly in the liver by stimulating THR-β to improve critical hepatic processes and reduce fibrosis1-3

A liver-directed treatment for noncirrhotic MASH and fibrosis1,4

1

THR-β signaling dysfunction worsens fibrosis progression4,5
THR-β signaling dysfunction worsens fibrosis progression
  • In MASH, impairment of THR-β signaling in the liver causes mitochondrial dysfunction, increased inflammation, and lipid buildup
  • This results in hepatocyte damage/death and fibrosis progression

2

Rezdiffra stimulates THR-β in the liver1,3,4
Rezdiffra selectively stimulates THR-β in the liver
  • Rezdiffra is a partial agonist of THR‑β, a nuclear receptor predominantly expressed in liver cells*
  • Rezdiffra stimulates THR-β signaling, regulating the expression of genes that improve critical processes in the liver, such as lipid metabolism and mitochondrial biogenesis

3

Improves metabolic function and reduces inflammation1-4
Improves metabolic function and reduces inflammation
  • Rezdiffra works to improve lipid metabolism (eg, reduces intrahepatic triglycerides and free fatty acids) and reduces inflammation in the liver
  • This helps to address drivers of disease progression, reduce liver damage, and improve liver health

A liver-directed treatment for noncirrhotic MASH and fibrosis1,4

1

THR-β signaling dysfunction worsens fibrosis progression4,5
  • In MASH, impairment of THR-β signaling in the liver causes mitochondrial dysfunction, increased inflammation, and lipid buildup
  • This results in hepatocyte damage/death and fibrosis progression

2

Rezdiffra stimulates THR-β in the liver1,3,4
  • Rezdiffra is a partial agonist of THR‑β, a nuclear receptor predominantly expressed in liver cells*
  • Rezdiffra stimulates THR-β signaling, regulating the expression of genes that improve critical processes in the liver, such as lipid metabolism and mitochondrial biogenesis

3

Improves metabolic function and reduces inflammation1-4
  • Rezdiffra works to improve lipid metabolism (eg, reduces intrahepatic triglycerides and free fatty acids) and reduces inflammation in the liver
  • This helps to address drivers of disease progression, reduce liver damage, and improve liver health
THR-β signaling dysfunction worsens fibrosis progression
Rezdiffra selectively stimulates THR-β in the liver
Improves metabolic function and reduces inflammation
*Actions of thyroid hormone outside the liver (including the heart and bones) are largely mediated through THR-α.1

Learn about oral, once-daily
dosing with Rezdiffra1

See Dosing
MASH=metabolic dysfunction-associated steatohepatitis, formerly known as NASH or nonalcoholic steatohepatitis; THR-α=thyroid hormone receptor alpha; THR-β=thyroid hormone receptor beta.
References:
  1. Rezdiffra. Prescribing Information. Madrigal Pharmaceuticals, Inc.
  2. Petta S et al. Liver International. 2024;44(7):1526-1536.
  3. Alonso-Merino E et al. Proc Natl Acad Sci. 2016;113(24):E3451-E3460.
  4. Karim G, Bansal MB. touchREV Endocrinol. 2023;19(1):60-70.
  5. Harrison SA et al. N Engl J Med. 2024;390(6):497-509.